Receptor phosphatases and cancer: Models for the therapeutic. Efficacy of somatostatin and LHRH analogues

Analogues of two hormones, Somatostatin and LHRH, have been found to stimulate receptor mediated tyrodine phosphatase activity and reverse the growth promotion of the tyrosine kinase class of oncogenes. These receptors are induced during transformation due to their activation by the increased tyrosine kinase found in many cancers. The prevalence of tyrosine phosphatase stimulating receptors on many cancers suggests that these hormones, or their longer acting and more selective analogues, could have clinical efficacy in the treatment of sensitive tumors. A model is developed from existing observations integrating these receptor mediated tyrosine phosphatases into the general picture of control of cell growth.